Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?

@article{Axelsson2008IsFG,
  title={Is fetuin-A/alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease?},
  author={Jonas Axelsson and Xin Wang and Markus Ketteler and Abdul Rashid Qureshi and Olof Heimb{\"u}rger and Peter Barany and Bengt Lindholm and Louise Nordfors and Peter Stenvinkel},
  journal={American journal of nephrology},
  year={2008},
  volume={28 4},
  pages={669-76}
}
INTRODUCTION Components of the metabolic syndrome are highly prevalent in chronic kidney disease (CKD) patients--some of which paradoxically appear to predict an improved outcome in this population. We hypothesized that the circulating calcification inhibitor fetuin-A/AHSG, which is also a natural inhibitor of the tyrosine kinase insulin receptor, could be one factor explaining the association between increased fat mass and a survival advantage in CKD and thus conducted an explorational study… CONTINUE READING